Clinical Trial Update: Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI) [Phase 4]

View source ↗

Summary

A Phase 4 pharmacokinetic study evaluated fidaxomicin in patients with inflammatory bowel disease who have Clostridioides difficile infection.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clostridioides Difficile Infection
• Inflammatory Bowel Disease

Drugs mentioned

• Dificid (fidaxomicin)

Snippet

Sponsor: Astellas Pharma Europe Ltd. | Conditions: Inflammatory Bowel Disease (IBD), Clostridium Difficile Infection (CDI) | Phase 4 | Status: COMPLETED